About us
Who we are
who we are
NOWDiagnostics
(NOWDx)
Our Approach
NOWDiagnostics (NOWDx) develops and manufactures the First To Know® Syphilis Test as well as other diagnostic tests. Its patented approach enables virtually any immunological assay to be accurately performed in one step using a small amount of capillary blood, yielding results in minutes. With over 89 patents issued and pending, NOWDx’s First To Know and ADEXUSDx® product lines are available in markets worldwide.
Our History
Founded in 2013, with headquarters and manufacturing in Springdale, Arkansas, NOWDx envisions a world where people have greater access to in-home testing with results in minutes. NOWDx is committed to changing healthcare by providing accessible, affordable, and accurate testing for all.
First to know
In the news
-
NOWDiagnostics and Labcorp Collaborate to Expand Access to the Only FDA-Marketing Authorized Over-the-Counter Syphilis Test in the U.S.
Read MoreAs syphilis cases surge nationwide, the collaboration will bring the First To Know over-the-counter test to clinicians and patients across professional and hospital settings NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today announced that Labcorp, a global leader of innovative and comprehensive laboratory services, will be the exclusive U.S. distributor…
-
NOWDiagnostics First To Know Syphilis Test Receives FDA De Novo Marketing Authorization for Over-the-Counter Use
Read MoreFirst and only rapid syphilis test with in-home results in minutes, addressing growing epidemic SPRINGDALE, ARK. – August 16, 2024 – NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization to its First To Know® Syphilis Test for…
Key Staff
